Literature DB >> 2983545

The use of multiple restriction fragment length polymorphisms in prenatal risk estimation. I. X-linked diseases.

A G Clark.   

Abstract

An analytical procedure for estimating the risk of X-linked diseases based on presence/absence of a series of restriction sites is presented. Multiple-locus linkage phase of the carrier mother is first inferred from previous offspring, from parents, and by molecular means. Bayesian risk estimates are then obtained using this information and the recombination-segregation distribution. The improvement afforded by using multiple flanking markers rather than a single marker is dramatic. Whereas the upper bound on the probability that a family will be informative using a single diallelic X-linked marker is .5, in the case of m markers, the bound on the probability of an informative family becomes 1 - .5m. With a single linked marker, the precision in the risk estimate is bounded by the frequency of recombination, whereas the requirement of very tight linkage is relaxed somewhat when multiple flanking markers are used. Recombination interference and multiple-locus linkage disequilibria can further improve the risk estimates, but it is important to understand how the statistical confidence in these parameters affects the reliability of the risk estimates.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2983545      PMCID: PMC1684547     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  21 in total

Review 1.  Report of the Committee on Human Gene Mapping by Recombinant DNA Techniques.

Authors:  M H Skolnick; H F Willard; L A Menlove
Journal:  Cytogenet Cell Genet       Date:  1984

2.  Use of restriction fragment length polymorphisms for genetic counseling: population genetic considerations.

Authors:  M A Asmussen; M T Clegg
Journal:  Am J Hum Genet       Date:  1982-05       Impact factor: 11.025

3.  Estimation of the marker gene frequency and linkage disequilibrium from conditional marker data.

Authors:  A Chakravarti; C C Li; K H Buetow
Journal:  Am J Hum Genet       Date:  1984-01       Impact factor: 11.025

4.  Genetic mapping of the human X chromosome by using restriction fragment length polymorphisms.

Authors:  D Drayna; K Davies; D Hartley; J L Mandel; G Camerino; R Williamson; R White
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

5.  A polymorphic DNA marker genetically linked to Huntington's disease.

Authors:  J F Gusella; N S Wexler; P M Conneally; S L Naylor; M A Anderson; R E Tanzi; P C Watkins; K Ottina; M R Wallace; A Y Sakaguchi
Journal:  Nature       Date:  1983 Nov 17-23       Impact factor: 49.962

6.  Utility and efficiency of linked marker genes for genetic counseling. III. Proportion of informative families under linkage disequilibrium.

Authors:  A Chakravarti
Journal:  Am J Hum Genet       Date:  1983-07       Impact factor: 11.025

7.  Theoretical models of genetic map functions.

Authors:  U Liberman; S Karlin
Journal:  Theor Popul Biol       Date:  1984-06       Impact factor: 1.570

8.  Toward a complete linkage map of the human X chromosome: regional assignment of 16 cloned single-copy DNA sequences employing a panel of somatic cell hybrids.

Authors:  P Wieacker; K E Davies; H J Cooke; P L Pearson; R Williamson; S Bhattacharya; J Zimmer; H H Ropers
Journal:  Am J Hum Genet       Date:  1984-03       Impact factor: 11.025

9.  Strategies for multilocus linkage analysis in humans.

Authors:  G M Lathrop; J M Lalouel; C Julier; J Ott
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

Review 10.  Construction of a genetic linkage map in man using restriction fragment length polymorphisms.

Authors:  D Botstein; R L White; M Skolnick; R W Davis
Journal:  Am J Hum Genet       Date:  1980-05       Impact factor: 11.025

View more
  1 in total

1.  Linkage analysis of Norrie disease with X-chromosomal ornithine aminotransferase.

Authors:  J B Bateman
Journal:  Trans Am Ophthalmol Soc       Date:  1992
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.